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Abstract When oxygen becomes limiting, cells shift primarily
to a glycolytic mode for generation of energy. A key regulator
of glycolytic £ux is fructose-2,6-bisphosphate (F-2,6-BP), a po-
tent allosteric regulator of 6-phosphofructo-1-kinase (PFK-1).
The levels of F-2,6-BP are maintained by a family of bifunc-
tional enzymes, 6-phosphofructo-2-kinase/fructose-2,6-bisphos-
phatase (PFKFB or PFK-2), which have both kinase and phos-
phatase activities. Each member of the enzyme family is
characterized by their phosphatase:kinase activity ratio (K:B)
and their tissue-speci¢c expression. Previous work demonstrated
that one of the PFK-2 isozyme genes, PFKFB-3, was induced by
hypoxia through the hypoxia-inducible factor-1 (HIF-1) path-
way. In this study we examined the basal and hypoxic expres-
sion of three members of this family in di¡erent organs of mice.
Our ¢ndings indicate that all four isozymes (PFKFB-1^4) are
responsive to hypoxia in vivo. However, their basal level of
expression and hypoxia responsiveness varies in the di¡erent
organs studied. Particularly, PFKFB-1 is highly expressed in
liver, heart and skeletal muscle, with the highest response to
hypoxia found in the testis. PFKFB-2 is mainly expressed in
the lungs, brain and heart. However, the highest hypoxia re-
sponses are found only in liver and testis. PFKFB-3 has a var-
iable low basal level of expression in all organs, except skeletal
muscle, where it is highly expressed. Most importantly, its hyp-
oxia responsiveness is the most ample of all three genes, being
strongly induced in the lungs, liver, kidney, brain, heart and
testis. Further studies showed that PFKFB-1 and PFKFB-2
were highly responsive to hypoxia mimics such as transition
metals, iron chelators and inhibitors of HIF hydroxylases, sug-
gesting that the hypoxia responsiveness of these genes is also
regulated by HIF proteins. In summary, our data demonstrate
that PFK-2 genes are responsive to hypoxia in vivo, indicating a
physiological role in the adaptation of the organism to environ-
mental or localized hypoxia/ischemia.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The ability to respond to hypoxia is an essential evolution-
ary adaptation in higher vertebrates. Hypoxia could be caused
by a generalized reduction in oxygen delivery, such as in alti-
tude and pulmonary diseases, or by disruption in the local
blood supply, such as in ischemic disorders. Important in
the adaptations to hypoxia is the activation of genes that
ameliorate or compensate for the oxygen de¢cit. At a systemic
level, there is an increase in erythropoietin that increases he-
moglobin production and the oxygen-carrying capacity of cir-
culating blood. At the tissue level, hypoxia activates the genes
of several angiogenic factors that promote local neo-circula-
tion, and at the cellular level, the lack of oxygen stimulates the
expression of glucose transporters and glycolytic enzymes that
compensate for the reduced activity of the mitochondrial res-
piratory chain [1^3]. This change from aerobic respiration to
glycolysis is essential for cell survival in hypoxic conditions.
Most interestingly, tumors have a high glycolytic activity even
in normoxic conditions, a phenomenon described by Warburg
more than 70 years ago [4]. The rate of glucose utilization via
the glycolytic pathway is coordinated with other processes
that also use glucose, notably gluconeogenesis and the pentose
pathway. Phosphofructokinase (PFK-1) is the key regulatory
enzyme that controls the glucose £ux through the glycolytic
pathway. It is allosterically activated by ADP and inhibited by
ATP and citrate. However, recent evidence indicates that fruc-
tose-2,6-bisphosphate (F-2,6-BP) is the most potent allosteric
activator of PFK-1 and an inhibitor of fructose-1,2-bisphos-
phatase [5]. Because of the antagonistic e¡ects in these en-
zymes, F-2,6-BP plays a critical role in the opposing glycolytic
and gluconeogenic pathways. Since glycolysis requires the
presence of F-2,6-BP, it is not unexpected that this compound
is present in all eukaryotic cells, from yeast to mammals. A
single family of bifunctional 6-phosphofructo-2-kinase/fruc-
tose-2,6-bisphosphatase (PFKFB or PFK-2) enzymes is re-
sponsible for maintaining the cellular levels of F-2,6-BP by
synthesizing and degrading this compound at distinctive active
sites in each enzyme type. That is, the kinase site synthesizes
F-2,6-BP from F-6-P and ATP whereas the phosphatase site
degrades F-2,6-BP to F-6-P and Pi [6].
Since the isolation of PFKFB-1 from rat liver and skeletal
muscle tissues, several other mammalian isozymes have been
identi¢ed: in heart (PFKFB-2), in testis (PFKFB-4), and a
ubiquitous form (PFKFB-3), present in placenta, brain and
most tumor cells (reviewed in [6]). These isozymes are encoded
by four di¡erent genes, PFKFB-1^4, located in di¡erent chro-
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mosomes [7]. The level of expression and activity of these
enzymes is controlled by hormones and metabolites [8,9]. Im-
portantly, tissue-speci¢c isoforms are not completely exclusive
and several tissues express more than one isoform. This multi-
ple expression suggests that each isozyme plays a key role in
di¡erent physiologic conditions or in response to di¡erent
hormonal stimulation. Despite a great structural similarity
of all isoforms, there are signi¢cant functional di¡erences in
their kinase and phosphatase activities. For example, the
PFKFB-3 form, which is highly expressed in placenta and
in tumors, has a very high kinase:phosphatase ratio, thus
favoring the accumulation of F-2,6-BP and enhancing glycol-
ysis [10]. Two forms (constitutive and inducible) that di¡er in
23 nucleotides in the C-terminal domain of the PFKFB-3 gene
have been described [11]. These two variants result from alter-
native splicing of the PFKFB-3 gene. The increased levels of
PFKFB-3 expression in tumors, specially its inducible form,
may explain the Warburg phenomenon present in malignant
cells [12,13]. Possibly, many more splice variants of PFKFB-3
exist; Kessler and Eschrich [14] have shown the occurrence of
six splice variants of PFKFB-3 in human brain. Watanabe et
al. [15,16] reported on the existence of eight splice isoforms of
ubiquitous PFKFB-3 in rat brain and heart. The role of these
variants in di¡erent tissues is not yet clear.
When oxygen is limiting, cells must rely on glycolysis to
meet their energy demands (Pasteur e¡ect). This adaptation
from aerobiosis to anaerobiosis involves the activation of
genes that facilitate glucose transport and utilization [17].
The regulation of gene expression by hypoxia is linked to
the activation of a hypoxia-inducible transcriptional complex
(HIF-1) that binds to speci¢c enhancer elements in hypoxia-
responsive genes [18]. Recently we reported that one member
of the PFK-2 family, PFKFB-3, is highly induced by hypoxia
in various cell lines. The hypoxic activation of the PFKFB-3
gene was found to be absolutely dependent on HIF-1 activity,
since HIF-1K-negative cells showed no hypoxic activation of
this gene [12]. Furthermore, transition metals, iron chelators
and oxoglutarate analogs, which mimic hypoxia by inhibiting
hydroxylases that negatively regulate both the level and activ-
ity of HIF-1K [19^22], also induced the expression of PFKFB-
3. Here, we present animal studies that show the hypoxic
induction of the PFKFB-3 gene in vivo. Furthermore, we
extend our observation of the e¡ect of hypoxia on the expres-
sion of the other members of the PFKFB family in vitro and
in vivo.
2. Materials and methods
2.1. Animals and cell cultures
All animal studies were performed in accordance with the National
Institute of Health guidelines for the use of experimental animals and
all animal protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) of Thomas Je¡erson University.
C57BL/6 mice (10^12 weeks old and 20^25 g body weight) were ob-
tained from the Jackson Laboratory (Bar Harbor, ME, USA). For
hypoxia in vivo, mice were placed for 6 h in a modular incubator
chamber (Billup-Rothenburg, Forma Scienti¢c, Marietta, OH, USA)
and £ushed with a gas mixture, containing 7.5% oxygen and 92.5%
nitrogen. Animal were killed immediately following extraction from
the hypoxic chamber and their tissues frozen in liquid nitrogen for
total RNA extraction. Hep3B, A549 and HeLa cells were obtained
from the American Type Culture Collection (Rockville, MD, USA)
and grown according to ATCC protocols. For hypoxic treatment, the
culture plates were placed for 6 h in a modular incubator chamber
(Billup-Rothenburg) and £ushed with a gas mixture, containing 0.5%
oxygen, 5% carbon dioxide and 94.5% nitrogen.
Chemicals were obtained from Sigma, except dimethyloxalylglycine,
which was provided by Dr. P. Ratcli¡e (Oxford, UK).
2.2. RNA isolation
Total RNA was extracted from cells or mouse organs using the acid
guanidinium^phenol^chloroform extraction method described by
Chomczynski and Sacchi [23]. Cells or mouse tissue were extracted
with 2 ml of guanidine isothiocyanate solution (Ultra Pure) consisting
of 4 M guanidine isothiocyanate, 50 mM Tris^HCl (pH 7.5), 25 mM
EDTA and 0.1 M 2-mercaptoethanol directly in the plates. Sequen-
tially, 0.2 ml of 2 M sodium acetate, pH 4.0, 2 ml of phenol (water-
saturated) and 0.4 ml of chloroform^isoamyl alcohol mixture (49:1)
were added to cell lysate, with thorough mixing after the addition of
each reagent. RNA was precipitated with an equal volume of 2-prop-
anol. RNA pellets were washed with 75% ethanol and dissolved in
nuclease-free water.
2.3. Plasmid construction
The plasmid for synthesis of rat or human PFKFB-1 probes were
made by synthesis of a cDNA using rat liver or A549 cell total RNA
and speci¢c primers as follows: human and rat PFKFB-1 cDNAs
were ampli¢ed using forward primer 5P-ACAGGAACTAT-
GAATTCTTTC-3P and reverse primer 5P-ACGTCGAAGATCTT-
GATGTAG-3P. These oligonucleotides correspond to nucleotide se-
quences 465^485 and 870^850 of rat PFKFB-1 cDNA, respectively
(GenBank1 accession number NM_012621). These fragments of
cDNA for rat and human PFKFB-1 mRNA were digested with
EcoRI and BglII and cloned into plasmid pBluescript II KSþ (Stra-
tagene, La Jolla, CA, USA) for riboprobe preparation. The plasmids
contained a 387-base protected fragment of rat or human PFKFB-1
cDNA, were digested with XhoI and used as a template for in vitro
transcription of radiolabeled antisense probe using T7 RNA polymer-
ase and [K-32P]UTP. The rat probe was suitable for detecting PFKFB-
1 expression in both rat and mouse.
The plasmids for synthesis of mouse or human PFKFB-2 probe
were made by synthesis of a cDNA using mouse heart or HeLa cell
total RNA and primers as follows: mouse and human PFKFB-2
cDNA was ampli¢ed using forward primer 5P-CTTGACCCAGA-
CAACTATG-3P and reverse primer 5P-ACTCCCCACCAGGG-
TATCG-3P. These oligonucleotides correspond to nucleotide sequen-
ces 655^673 and 1138^1119 of mouse PFKFB-2 cDNA, respectively
(GenBank1 accession number NM_008825). For human PFKFB-2
cDNA these oligonucleotides correspond to nucleotide sequences
696^714 and 1179^1160, respectively (GenBank1 accession number
NM_052034). These polymerase chain reaction (PCR) fragments of
cDNA for PFKFB-2 mRNA were cloned into plasmid pCR II-TOPO
using TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). An
EcoRI-KpnI fragment from plasmid containing the human or mouse
fragment of PFKFB-2 cDNA was subcloned into plasmid pBluescript
II KSþ for RNase protection assays. These plasmids digested with
XbaI and used as a template for in vitro transcription of a radio-
labeled antisense probe contained a 424-base protected fragment using
T3 RNA polymerase and [K-32P]UTP.
The plasmids for synthesis of mouse ubiquitous PFKFB-3, mouse
glucose transporter-1 (Glut-1) and mouse 18S ribosomal RNA probe
for RNase protection assays have been described previously [12]. The
18S ribosomal RNA antisense probe was used to evaluate total RNA.
All constructs were con¢rmed by sequencing analysis.
For the PFKFB-4 probe, mouse PFKFB-4 cDNA was ampli¢ed
from total testis RNA using forward primer 5P-GGGATGG-
CGTCTCCACGGG-3P and reverse primer 5P-GGCACTGGAAA-
CAGCTCGG-3P. The nucleotides correspond to sequences 23^41
and 439^421 of the published mouse cDNA (GenBank1 accession
number AK079023). The cDNA fragment was cloned in pBluescript
II SKþ vector and utilized for RNase protection assays.
2.4. Preparation of antisense probes for ribonuclease protection assay
Radiolabeled probes for RNase protection assay were synthesized
using T7 or T3 RNA polymerase kit (Roche Molecular Biochemicals)
and [K-32P]UTP, according to the manufacturer’s instructions. For
RNase protection assays water solutions of total RNA were dried
in speed vacuum and dissolved in 25 Wl of 80% formamide hybridi-
zation bu¡er containing labeled probes. Samples were preincubated
for 5 min at 85‡C and then incubated for 16 h at 45‡C as described
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previously [11]. The extracted, protected probe fragments were run on
a 6% polyacrylamide sequencing gel in 1UTris^borate^EDTA bu¡er
for 2 h at 50 mA. The gel was then dried and exposed to X-ray ¢lm
(Hyper¢lm MP, Amersham, Arlington Heights, IL, USA) at 370‡C.
Expression of mRNA was quanti¢ed using storage phosphor tech-
nology (Molecular Dynamics, Sunnyvale, CA, USA). The intensity
of each mRNA band was normalized to the 18S ribosomal RNA
level.
2.5. Statistical analysis
Data comparing all PFKFB and Glut-1 mRNA expressions were
subjected to analysis of variance followed by Fisher’s method for
evaluation of di¡erences between groups. Comparison of PFKFB
and Glut-1 mRNA was subjected to Student’s t-test. Values of
P6 0.05 were considered statistically signi¢cant.
3. Results
3.1. E¡ect of hypoxia on PFKFB gene expression in vivo
Mice were maintained for 6 h in a chamber £ushed contin-
uously with a gas mixture containing 7.5% oxygen and 92.5%
nitrogen (environmental hypoxia), total RNA was extracted
from di¡erent organs and PFKFB-1, 2 and 3 mRNAs were
readily quanti¢ed by RNase protection assays.
3.1.1. PFKFB-1. Exposure of mice to environmental hyp-
oxia moderately induced PFKFB-1 mRNA levels in the liver
and skeletal muscle as compared to control mice. Surprisingly,
the strongest response was found in the testis, whereas hyp-
oxia had insigni¢cant e¡ect in brain, heart or kidneys (Fig.
1A). It is important to note that basal expression was highly
variable, being intense in liver, heart and muscle. Densitomet-
ric quanti¢cation of the e¡ect of hypoxia on PFKFB-1
mRNA expression is shown in Fig. 1A. The intensity of
each PFKFB-1 mRNA band was normalized to the 18S
rRNA level in each sample. In a mean of four experiments,
the PFKFB-1 transcript levels were signi¢cantly increased in
the testis (+230%; P6 0.01), liver (+33%; P6 0.05) and skel-
etal muscle (+27%; P6 0.05). The levels of PFKFB-1 mRNA
Fig. 1. Hypoxic expression of PFKFB-1 and PFKFB-2 mRNA in mouse organs. Mice were exposed to hypoxia and their RNA analyzed by
RNase protection assays. Bands are autoradiographs of representative assays utilizing total organ RNA from normal (Nx) and hypoxic (Hx)
mice. Bands represent autoradiographs utilizing speci¢c PFKFB-1 (A) or PFKFB-2 (B) probes. Densitometry measurements with S.D. are ra-
tios between each organ-speci¢c mRNA and their 18S ribosomal RNA.
FEBS 27797 5-11-03
O. Minchenko et al./FEBS Letters 554 (2003) 264^270266
in the lungs of control and hypoxia-treated mice were unde-
tectable (data not shown).
3.1.2. PFKFB-2. Similar analysis as above was conducted
in the organs of normoxic and hypoxic mice for the expression
of the PFKFB-2 gene. As shown in Fig. 1B, induction of
PFKFB-2 mRNA expression was observed in the lungs, liver
and testis, with the highest induction occurring in the testis.
Basal levels were the highest in heart, lungs and brain. Quan-
ti¢cation of the e¡ect of hypoxia on the expression of
PFKFB-2 mRNA in di¡erent organs is shown (bottom). In
a mean of four experiments, the PFKFB-2 transcript levels
were signi¢cantly increased in the testis (9-fold; P6 0.001),
lungs (+76%; P6 0.05) and liver (+101%; P6 0.05). No sig-
ni¢cant changes were found in the brain and kidneys, whereas
a small but signi¢cant down-regulation of expression was ob-
served in the heart (323%; P6 0.05) and skeletal muscle
(331%; P6 0.05).
3.1.3. PFKFB-3. The ubiquitously expressed isoform
PFKFB-3 was reported to be highly responsive to oxygen
deprivation in various cell lines [12]. The in vivo studies
shown in Fig. 2A con¢rmed its stimulation by hypoxia in
all tissues tested with the exception of skeletal muscle. As
quanti¢ed in Fig. 2A (bottom), the mean PFKFB-3 transcript
levels from four experiments were signi¢cantly increased in
the lungs (+91%; P6 0.01), liver (+94%; P6 0.01), kidney
(+115%; P6 0.05), brain (+210%; P6 0.05), heart (+84%;
P6 0.01) and testis (+230%; P6 0.05). In the skeletal muscle,
expression of PFKFB-3 mRNA was decreased (350%;
P6 0.05).
3.1.4. PFKFB-4. The hypoxia responsiveness of the testis
isoform PFKFB-4 was tested using RNase protection assay
with a speci¢c testis probe and total RNA obtained from
normal and hypoxic mouse testis. As shown in Fig. 2B, the
testicular isoform has a signi¢cant response to hypoxia in
vivo. The expression of PFKFB-4 in other tissues was not
investigated.
We also studied the e¡ect of environmental hypoxia on a
control gene, Glut-1, a gene well characterized for its hypoxia
response [16]. Hypoxia strongly increased expression of Glut-1
mRNA in the lungs, brain, heart and testis, slightly induced
its expression in the liver and kidneys, but did not change
signi¢cantly in skeletal muscle (Fig. 2C).
Fig. 2. Hypoxic expression of PFKFB-3, PFKFB-4 and Glut-1 in mouse organs. Autoradiographs of representative RNase protection assays of
PFKFB-3 (A), PFKFB-4 (B) and Glut-1 (C) mRNA (upper) and 18S ribosomal RNA (bottom) using total RNA extracted from organs of nor-
moxic (Nx) or hypoxic (Hx) animals. Densitometry measurements with S.D. of each speci¢c mRNA are expressed as ratios between individual
organs and their respective 18S RNA.
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3.2. E¡ect of hypoxia on PFKFB-1 and PFKFB-2 in
cultured cells
To investigate further the mechanisms of hypoxia-induced
up-regulation of PFKFB-1 and PFKFB-2 mRNA expression,
we studied the e¡ect of hypoxia and hypoxia mimics on the
expression of these genes in various cell lines. As shown in
Fig. 3A, hypoxia signi¢cantly induced PFKFB-1 mRNA ex-
pression in HeLa and A549 cells, while no expression was
observed in Hep3B cells (not shown). Moreover, desferrox-
amine (an iron-chelating agent), cobaltous chloride (transition
metal) and dimethyloxalylglycine (oxoglutarate analog), which
are known to mimic hypoxia, also had a stimulatory e¡ect on
the expression of PFKFB-1 mRNA in these cells. These
agents inhibit HIF hydroxylase enzymes that are involved in
the oxygen-dependent hydroxylation of residues that control
either the proteasomal degradation or the transactivation ac-
tivity of HIF proteins. Similar analysis was conducted for the
expression of the PFKFB-2 gene. As shown in Fig. 3B, hyp-
oxia and dimethyloxalylglycine signi¢cantly induced PFKFB-
2 mRNA expression in HeLa and MCF-7 cells while minimal
or no e¡ect was observed in Hep3B and A549 cells. The Glut-1
control mRNA was induced by all stimuli, with variable in-
tensity, in all cell lines tested (not shown).
4. Discussion
During hypoxia, when oxygen is limiting, cells rely on gly-
colysis to sustain energy expenditure. The key step of glycol-
ysis commitment is controlled by PFK-1 (6-phosphofructo-1-
kinase) that phosphorylates fructose-6-P to produce fructose-
1,6-bisphosphate. This enzyme is allosterically regulated by
the AMP:ATP ratio. However, since 1980 it has become ap-
parent that the most potent allosteric activator of PFK-1 is F-
2,6-BP, the product of phosphorylation of fructose-6-P by a
family of enzymes known generically as phosphofructokinase-
2 (PFK-2) [5,6]. These enzymes contain both kinase and phos-
phatase activities at distinct active sites of the molecule. Thus,
F-2,6-BP levels are regulated by the relative kinase and phos-
phatase activities which depend on various physiologic or
pathologic conditions of the cell. The K:B ratio (kinase/bis-
phosphatase) in a cell is ultimately determined by the types of
isoforms present, the levels of several glycolytic or gluconeo-
Fig. 3. A: Hypoxic expression of PFKFB-1 and PFKFB-2 mRNA in cultured cell lines. Autoradiographs of representative RNase protection
assays of PFKFB-1 mRNA (A) and PFKFB-2 (B) using total RNA extracted from HeLa, A549, MCF-7 and Hep3B cells in the presence of di-
methyloxalylglycine (I), hypoxia (Hx), desferroxamine (Df) or cobalt (Co). Densitometry measurements of PFKFB mRNAs are expressed as ra-
tios between individual cell cultures and their respective 18S RNAs. Bar represents S.D. of the mean.
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genic metabolites and post-translational modi¢cations of the
enzymes, mainly phosphorylation. In the heart, acute ischemia
induces rapid activation of AMP-dependent kinase that phos-
phorylates Ser-466 leading to a two-fold increase in the Vmax
of PFKFB-2 [24]. Previous studies by our laboratory had
shown that sustained hypoxia up-regulates the expression of
the PFKFB-3 gene and that this activation was mediated by a
mechanism that depended on the activation of the HIF-1
transactivation complex [12]. Importantly, because PFKFB-3
lacks a serine phosphorylation residue that is critical for the
down-regulation of its kinase activity, it has the highest K:B
ratio of all PFKFB isozymes and greatly promotes glycolysis
under conditions of limited oxygen supply [6]. The studies
presented here were designed to investigate the expression of
the PFKFB-1^4 isozymes under hypoxic conditions in vivo
and to determine the mechanisms of hypoxia-induced up-reg-
ulation of these genes.
The PFKFB-1 gene encodes one form of PFK-2 isozyme
originally found in liver and muscle tissues [25,26]. Using
RNase protection assays we found detectable basal levels of
expression of PFKFB-1 mRNA in the heart and skeletal
muscle, with slightly lower levels in the liver. Low or unde-
tectable basal levels were found in lungs, kidneys, brain and
testis. Exposure of mice to environmental hypoxia induced
moderate PFKFB-1 expression in the liver and skeletal muscle
and, surprisingly, a strong induction of expression in the tes-
tis. These results indicate that the PFKFB-1 gene is hypoxia-
inducible in vivo. However, the intensity of the hypoxic in-
duction appears to vary in an organ-, tissue- or cell-speci¢c
manner. To investigate further the mechanisms of hypoxia-
induced up-regulation of the PFKFB-1 gene we utilized sev-
eral hypoxia mimics that are known to stimulate the forma-
tion of HIF-1 complex. Cobalt, desferroxamine and dimethy-
loxalylglycine showed a similar potency as hypoxia in the
induction of PFKFB-1 mRNA expression in HeLa and A549
cells. However, no e¡ect was found in Hep3B cells, which
conforms with the variability of expression found in vivo.
The induction of the HIF-1 complex is mediated by stabiliza-
tion of its K-subunits that are rapidly degraded by the pro-
teasomal system under oxic conditions. Oxygen sensing is
mediated by a group of oxygen- and iron-dependent HIF
hydroxylases that utilize oxoglutarate as co-substrate. These
HIF hydroxylase enzymes regulate both the survival and the
transcriptional activity of the HIF proteins. The e¡ect of hyp-
oxia can be mimicked by transition metals such as cobalt, iron
chelators such as desferroxamine and by competitive inhibi-
tors of oxoglutarate, such as dimethyloxalylglycine, all of
which inhibit the activity of hydroxylase enzymes [19^22].
Thus, inhibition of these enzymes induces HIF-K stability
and induces the transcriptional activity of the HIF-1 complex
under normoxic conditions. The ¢nding that treatment of
HeLa and A549 cells with oxoglutarate analogs, cobalt and
desferroxamine signi¢cantly induces PFKFB-1 mRNA
strongly suggests the involvement HIF-K proteins in the hyp-
oxia inducibility of the PFKFB-1 gene.
The PFKFB-2 gene encodes the PFK-2 isoform originally
found in the heart [27,28]. Our results indicate that the heart
form was expressed at high levels not only in the heart but
also in the brain and lungs. In vivo, hypoxia induced moder-
ate expression in the lung and liver and very strong stimula-
tion in the testis. No induction or even mild inhibition was
found in the heart, kidney, brain and skeletal muscle. Thus, as
shown for the PFKFB-1 gene, PFKFB-2 was also hypoxia-
inducible in vivo in a tissue-speci¢c manner. We also studied
the e¡ect of hypoxia on the expression of PFKFB-2 in cul-
tured cells. Our results showed that hypoxia and hypoxia
mimics (oxoglutarate analogs) induced PFKFB-2 in HeLa
and MCF-7 cells with minor or no e¡ect in Hep3B or A549
cells. Unfortunately, these genes were not expressed in HIF-
1K-de¢cient cells and the direct role of HIF complexes in
hypoxia induction could not be tested in HIF nullizygous
cell lines, as shown for the PFKFB-3 gene [12].
Previously, we have reported that the PFKFB-3 gene was
highly induced by hypoxia in various cell lines and that the
e¡ect of hypoxia was reproduced by hypoxia mimics. In this
study we show that environmental hypoxia induces the
PFKFB-3 gene in vivo in all tested organs with the exception
of skeletal muscle. Thus, the observed hypoxic regulation of
PFKFB-3 mRNA in cell cultures has now been extended to
an in vivo situation, indicating the physiological signi¢cance
of this particular isoform in the adaptive response to hypoxia.
Analysis of tissue distribution of PFKFB type 1, 2 and 3
mRNAs showed that liver, lungs, kidneys, heart, brain, testis
and skeletal muscle have di¡erent levels of PFK-2 isozymes in
normoxic and hypoxia-treated mice. The lungs have high
basal levels of PFKFB-2 and PFKFB-3 mRNA. In addition,
both isozymes were induced by hypoxia. The liver has higher
basal levels of PFKFB-1 and much lower PFKFB-2 and
PFKFB-3 mRNA. All three isozymes were induced by hyp-
oxia. The brain and kidneys have medium basal levels of
PFKFB-3, low levels of PFKFB-2 and much lower PFKFB-
1 mRNA. Only PFKFB-3 was induced by hypoxia. The heart
has high basal levels of PFKFB-2 and PFKFB-1 and low
levels of PFKFB-3 mRNA. Hypoxia induced expression of
PFKFB-3 and had almost no signi¢cant e¡ect in the other
two isoforms. In contrast to the heart, skeletal muscle has
low levels of PFKFB-2 and high levels of PFKFB-1 and
PFKFB-3 that were not responsive to hypoxia or even slightly
inhibited. Testis had low basal levels of all three enzymes but
surprisingly, it was the organ that showed the strongest re-
sponse to hypoxic stimulation, including the speci¢c PFKFB-
4 isoform. The explanation for the strong hypoxic induction
in this organ is unclear. In general, our ¢ndings con¢rm the
earlier observations that tissue-speci¢c PFKFB enzyme ex-
pression is not completely exclusive [5,6,29]. Of interest, anal-
ysis of Glut-1, a gene well characterized for its hypoxia re-
sponsiveness [17], also showed great variations with respect to
basal expression and hypoxia responses in vivo. Furthermore,
its hypoxia responsiveness parallels that of the PFKFB-3
gene, having stimulated expression in most organs except skel-
etal muscle. No correlation was found between the expression
of the di¡erent isoforms and the in vivo expression of HIF-1,
as reported by Stroka et al. [30].
In summary, our study provides evidence that all four
tested PFK-2 genes are hypoxia-responsive in vivo but the
regulation of their expression following hypoxic treatment is
di¡erent and appears to occur in a cell-speci¢c manner. More-
over, the hypoxic induction of PFKFB-1, 2 and 4, as already
shown for PFKFB-3, is most likely HIF-1-dependent. The
mechanisms underlying the expression of each isoform in dif-
ferent tissues remain unclear.
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